Search
Adagene Inc
ADAGAdd to Watchlist
3.750USD
+0.020+0.54%
Close 07-31 16:00（ET）Quotes delayed by 15 min
247.69MMarket Cap
LossP/E TTM
More Details of Adagene Inc Company
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Adagene Inc Info
Ticker SymbolADAG
Company nameAdagene Inc
IPO dateFeb 09, 2021
CEOLuo (Peter)
Number of employees138
Security typeDepository Receipt
Fiscal year-endFeb 09
Address4F, Building C14, No. 218, Xinghu Street
CitySUZHOU
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryChina
Postal code- -
Phone8651287773632
Websitehttps://www.adagene.com/
Ticker SymbolADAG
IPO dateFeb 09, 2021
CEOLuo (Peter)
Company Executives of Adagene Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.60M
+11.48%
Ms. She (Kristine) Xiaohong
Ms. She (Kristine) Xiaohong
Senior Vice President, Head of Clinical Operations
Senior Vice President, Head of Clinical Operations
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Wang (Ron) Yuren, Ph.D.
Dr. Wang (Ron) Yuren, Ph.D.
Head of Portfolio Management
Head of Portfolio Management
--
--
Dr. Shang Jin
Dr. Shang Jin
Senior Vice President of Global Regulatory Affairs
Senior Vice President of Global Regulatory Affairs
--
--
Dr. Zheng Songmao
Dr. Zheng Songmao
Associate Vice President of Research and Development
Associate Vice President of Research and Development
--
--
Dr. Zha Jiping, Ph.D.
Dr. Zha Jiping, Ph.D.
Executive Vice President of Clinical Development
Executive Vice President of Clinical Development
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
Ms. Ami Knoefler
Ms. Ami Knoefler
Vice President of Investor Relations and Corporate Communications
Vice President of Investor Relations and Corporate Communications
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.60M
+11.48%
Ms. She (Kristine) Xiaohong
Ms. She (Kristine) Xiaohong
Senior Vice President, Head of Clinical Operations
Senior Vice President, Head of Clinical Operations
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Wang (Ron) Yuren, Ph.D.
Dr. Wang (Ron) Yuren, Ph.D.
Head of Portfolio Management
Head of Portfolio Management
--
--
Dr. Shang Jin
Dr. Shang Jin
Senior Vice President of Global Regulatory Affairs
Senior Vice President of Global Regulatory Affairs
--
--
FAQs
Who are the top five shareholders of Adagene Inc?
The top five shareholders of Adagene Inc are: Dr. Peter (Peizhi) Luo, Ph.D.
How many institutions hold shares of Adagene Inc (ADAG)?
As of 2026Q1, 38 institutions hold shares of Adagene Inc, with a combined market value of approximately 13.55M, accounting for 20.51% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2119805.00.